Expert Outlook: TScan Therapeutics Through The Eyes Of 5 Analysts
Portfolio Pulse from Benzinga Insights
Analysts' ratings for TScan Therapeutics (NASDAQ:TCRX) over the last quarter show a mix of bullish and somewhat bullish sentiments. The average 12-month price target is $12.6, with a high of $15.00 and a low of $10.00. The company's financial metrics indicate challenges in revenue growth, ROE, and ROA, but it maintains a strong net margin.
August 13, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Analysts' ratings for TScan Therapeutics (NASDAQ:TCRX) show a mix of bullish and somewhat bullish sentiments. The average 12-month price target is $12.6, with a high of $15.00 and a low of $10.00. Financial metrics indicate challenges in revenue growth, ROE, and ROA, but the company maintains a strong net margin.
The mixed analyst ratings and the slight decrease in the average price target suggest a neutral short-term impact on TCRX. While the company faces challenges in revenue growth, ROE, and ROA, its strong net margin provides some positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100